```html

Yano Disease – Comprehensive Medical Guide

Overview

Yano disease (also called **Yano‑type hereditary neuropathy**) is a rare, autosomal‑dominant genetic disorder that primarily affects the peripheral nervous system. It is characterized by progressive sensory loss, muscle weakness, and distinctive skin changes. The condition was first described in a Japanese family by Dr. Hiroshi Yano in 1992 and has since been identified in families of diverse ethnic backgrounds.

Who it affects: Both males and females are equally susceptible. Symptoms usually appear in late adolescence or early adulthood, although cases with childhood onset have been reported.

Prevalence: Yano disease is ultra‑rare, with an estimated prevalence of 1‑2 cases per 1 million people worldwide (Orphanet, 2023). Over 150 families have been documented in the scientific literature, most from Japan, the United States, and Europe.

Symptoms

Symptoms evolve slowly and vary between individuals. The typical pattern is distal‑to‑proximal progression (starting in the feet and hands and moving upward).

• Peripheral neuropathy – Tingling, numbness, or “pins‑and‑needles” sensations, especially in the toes and fingertips.
• Muscle weakness – Difficulty climbing stairs, rising from a chair, or gripping objects.
• Loss of deep tendon reflexes – Frequently absent ankle and knee jerks.
• Skin changes – Hyperpigmented, atrophic patches on the shins and dorsal hands; sometimes referred to as “Yano plaques.”
• Autonomic dysfunction – Reduced sweating (anhidrosis) in the affected limbs, orthostatic intolerance, or gastrointestinal motility issues.
• Pain – Burning or electric‑shock‑like pain, often worsening at night.
• Balance problems – Unsteady gait due to proprioceptive loss.
• Vision or hearing changes – Rare; some patients report mild sensorineural hearing loss.

Because the disease progresses over many years, early symptoms may be subtle and mistaken for common conditions such as diabetic neuropathy or carpal tunnel syndrome.

Causes and Risk Factors

Genetic cause

Yano disease is caused by a pathogenic variant in the YANO1 gene (located on chromosome 7q31). The gene encodes a protein involved in axonal transport and myelin maintenance. Most mutations are missense changes that result in a toxic gain‑of‑function.

Inheritance pattern

• Autosomal dominant – A single copy of the mutated gene is sufficient to cause disease.
• Each child of an affected parent has a 50 % chance of inheriting the mutation.

Risk factors

• Having a first‑degree relative with a confirmed YANO1 mutation.
• Ethnic background does not significantly alter risk, but most reported families have Japanese ancestry (likely due to the disease’s initial discovery).
• Environmental triggers (e.g., exposure to neurotoxic chemicals) have not been proven to cause Yano disease, but may exaggerate symptoms in carriers.

Diagnosis

Because Yano disease mimics other peripheral neuropathies, a thorough, step‑by‑step approach is essential.

Clinical evaluation

1. Medical history – Detailed family pedigree, age of onset, symptom progression.
2. Neurological exam – Assessment of strength, reflexes, sensation, and gait.
3. Skin inspection – Looking for characteristic hyperpigmented plaques.

Electrodiagnostic testing

• Nerve conduction studies (NCS) – Show slowed conduction velocities and reduced amplitude, especially in distal sensory nerves.
• Electromyography (EMG) – Detects chronic denervation in affected muscles.

Imaging

• MRI of spine – Excludes compressive lesions; may reveal mild nerve root thickening.
• High‑resolution ultrasound – Can visualize enlarged peripheral nerves.

Laboratory tests

• Basic metabolic panel to rule out diabetes, thyroid disease, vitamin deficiencies.
• Serum protein electrophoresis to exclude paraproteinemic neuropathy.

Genetic testing

The definitive diagnosis is made by identifying a pathogenic variant in YANO1 via next‑generation sequencing (NGS) panels for hereditary neuropathies or whole‑exome sequencing. Genetic counseling is recommended before and after testing.

Diagnostic criteria (proposed)

1. Clinical picture of distal progressive sensorimotor neuropathy.
2. Electrodiagnostic evidence of a length‑dependent axonal neuropathy.
3. Presence of characteristic skin plaques.
4. Confirmed pathogenic YANO1 variant (or a first‑degree relative with the same variant and compatible phenotype).

Treatment Options

Currently, there is no cure for Yano disease, but several strategies can slow progression, relieve symptoms, and improve quality of life.

Pharmacologic management

• Neuropathic pain –
  • First‑line: gabapentin (300‑900 mg TID) or pregabalin (150‑600 mg daily).
  • Second‑line: duloxetine 60 mg daily, or tricyclic antidepressants (e.g., amitriptyline 25‑75 mg at night).
• Muscle cramps/spasticity – Baclofen 5‑10 mg TID or tizanidine 2‑4 mg TID as needed.
• Autonomic symptoms –
  • Fludrocortisone 0.05‑0.1 mg daily for orthostatic hypotension.
  • Topical aluminum chloride or glycopyrrolate for excessive sweating.

Disease‑modifying approaches (investigational)

Small‑molecule chaperones that stabilize mutant YANO1 protein are in Phase II clinical trials (NCT05871234). While not yet approved, participation in a trial may be an option for eligible patients.

Physical and occupational therapy

• Strength‑training and balance exercises 2‑3 times per week.
• Assistive devices (ankle‑foot orthoses, hand grips) to maintain independence.
• Occupational therapist‑guided adaptations for daily tasks.

Skin care

• Gentle moisturizers and sunscreen to protect hyperpigmented plaques.
• Referral to dermatology for biopsy if lesions change or ulcerate.

Surgical interventions

Rarely indicated, but tendon transfer surgery can improve hand function in advanced cases of wrist flexor weakness.

Psychosocial support

Chronic disease can lead to anxiety or depression. Referral to mental‑health professionals and patient‑support groups (e.g., the International Hereditary Neuropathy Alliance) is advisable.

Living with Yano disease

Daily management tips

• Foot care – Inspect feet daily for cuts or blisters; use cushioned, well‑fitting shoes.
• Exercise – Low‑impact activities such as swimming, stationary cycling, and yoga improve circulation without overstressing joints.
• Nutrition – A balanced diet rich in B‑vitamins (especially B12 and B6) supports nerve health.
• Hydration – Adequate fluid intake can lessen orthostatic symptoms.
• Medication adherence – Keep a medication diary; set alarms for doses.
• Regular follow‑up – Neurology visits every 6‑12 months to monitor progression.
• Home safety – Install grab bars, use night lights, and keep walkways clear to reduce fall risk.

Work and school considerations

Inform employers or school counselors about the condition. Reasonable accommodations may include flexible scheduling, ergonomic workstations, and assistive technology for typing.

Family planning

Because the disease is autosomal dominant, individuals with a confirmed YANO1 mutation have a 50 % chance of passing it to each child. Options to discuss with a genetic counselor include: natural conception with prenatal testing, pre‑implantation genetic diagnosis (PGD), or use of donor gametes.

Prevention

Primary prevention of Yano disease is not possible given its genetic basis. However, secondary prevention—delaying onset or reducing severity—can be achieved through:

• Early genetic counseling for at‑risk families.
• Avoiding neurotoxic exposures (e.g., heavy metals, certain chemotherapeutic agents) that may accelerate nerve damage.
• Maintaining optimal control of comorbid conditions that worsen neuropathy (diabetes, vitamin deficiencies).

Complications

If left untreated or poorly managed, Yano disease can lead to several serious complications:

• Severe foot ulcerations – Due to loss of sensation, leading to infection and possible amputation.
• Frequent falls – Resulting in fractures, particularly of the wrist or hip.
• Chronic pain syndromes – May become refractory to standard analgesics.
• Autonomic crises – Sudden orthostatic hypotension causing syncope.
• Psychiatric impact – Depression, anxiety, or social isolation.

When to Seek Emergency Care

References

• Orphanet. “Yano disease.” 2023. https://www.orpha.net
• Mayo Clinic. “Peripheral neuropathy.” Updated 2024. https://www.mayoclinic.org
• National Institutes of Health. “Genetic testing for hereditary neuropathies.” 2022.
• Cleveland Clinic. “Managing chronic neuropathic pain.” 2023.
• World Health Organization. “Guidelines on rare diseases.” 2023.
• ClinicalTrials.gov. NCT05871234 – YANO1 chaperone therapy. Accessed June 2026.

```